← All organizations
Highest phase reached
Phase 3
First clinical trial
Mar 1, 2006Last known activity
Nov 30, 2024
Timeline
2000s
- Jan 1, 2003
Innovative Therapies For Children with Cancer Consortium— Founded
Drugs by trial phase (34 distinct, 15 trials)
Phase 3 (2 own, 0 via acquisition)
Phase 2 (24 own, 0 via acquisition)
Phase 1 (8 own, 0 via acquisition)
Indications
Studied for
- Blast Crisis
- Bone Marrow Diseases
- Glioma
- Hematologic Diseases
- Leukemia
- Leukemia, Lymphoid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Accelerated Phase
- Leukemia, Myeloid, Acute
- Leukemia, Myeloid, Chronic-Phase
- Lymphoma
- Lymphoma, Non-Hodgkin
- Lymphoma, T-Cell
- Myeloproliferative Disorders
- Neoplastic Processes
- Philadelphia Chromosome
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Recent trials (15)
- NCT06679582CollaboratorPhase 1/Phase 2Nov 30, 2024
- NCT05740449CollaboratorPhase 1/Phase 2Oct 1, 2023
- NCT05745714CollaboratorPhase 1/Phase 2Oct 1, 2023
- NCT05751044CollaboratorPhase 1/Phase 2Oct 1, 2023
- NCT05658640CollaboratorPhase 1/Phase 2Apr 1, 2023
- NCT05429502CollaboratorPhase 1/Phase 2Dec 31, 2022
- NCT05476939CollaboratorPhase 3Sep 29, 2022
- NCT04258943CollaboratorPhase 1/Phase 2Mar 20, 2020
- NCT03793478CollaboratorPhase 1/Phase 2Aug 15, 2018
- NCT01887522CollaboratorPhase 2Jun 1, 2016
- NCT02303821CollaboratorPhase 1Dec 1, 2014
- NCT02233049CollaboratorPhase 2Oct 1, 2014
- NCT01844765CollaboratorPhase 2Aug 20, 2013
- NCT00742495CollaboratorPhase 1/Phase 2Mar 1, 2009
- NCT00306202CollaboratorPhase 1Mar 1, 2006
Details
- Founded
- GB Jan 1, 2003
- Last known activity
- Nov 30, 2024